aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2023-19-2-131-139ateroskleroz-907Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSПерсонификация сердечно-сосудистого риска: фокус на систему натрийуретических пептидовCardiovascular risk personification: focus on the natriuretic peptide systemhttps://orcid.org/0000-0002-6620-5960ХрячковаО. Н.KhryachkovaO. N.

Оксана Николаевна Хрячкова, канд. биол. наук, младший научный сотрудник лаборатории геномной медицины отдела экспериментальной медицины

650002, Кемерово, Сосновый бульвар, 6

Oksana N. Hryachkova, candidate of biological sciences, junior researcher, laboratory of genomic medicine

6, Sosnovy Blvd, Kemerovo, 650002

oksana_hryachkova@mail.ruhttps://orcid.org/0000-0002-4467-8732СиницкаяА. В.SinitskayaA. V.

Анна Викторовна Синицкая, канд. биол. наук, научный сотрудник лаборатории геномной медицины отдела экспериментальной медицины

650002, Кемерово, Сосновый бульвар, 6

Anna V. Sinitskaya, candidate of biological sciences, researcher, laboratory of genomic medicine

6, Sosnovy Blvd, Kemerovo, 650002

https://orcid.org/0000-0002-3002-2863ПонасенкоА. В.PonasenkoA. V.

Анастасия Валериевна Понасенко, канд. мед. наук, зав. лабораторией геномной медицины отдела экспериментальной медицины

650002, Кемерово, Сосновый бульвар, 6

Anastasia V. Ponasenko, candidate of medical sciences, head of the laboratory of genomic medicine, department of experimental medicine

6, Sosnovy Blvd, Kemerovo, 650002

Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»Federal State Budgetary Scientific Institution «Research Institute for Complex Issues of Cardiovascular Diseases»202310072023192131139Copyright © Хрячкова О.Н., Синицкая А.В., Понасенко А.В., 20232023Хрячкова О.Н., Синицкая А.В., Понасенко А.В.Khryachkova O.N., Sinitskaya A.V., Ponasenko A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/907

В кратком обзоре представлены современные данные о возможностях прогнозирования течения сердечно-сосудистых и других заболеваний, а также результаты оперативного лечения у пациентов с помощью оценки концентрации предсердного, мозгового натрийуретических пептидов, полиморфных вариантов генов этих пептидов и их рецепторов. Определены значимые перспективы дальнейших исследований в данном направлении с целью разработки прогностических молекулярно-генетических панелей для оценки риска развития инфаркта миокарда, артериальной гипертонии, сердечной недостаточности в рамках первичной и вторичной профилактики.

A brief review presents current data on the possibilities of predicting the course of cardiovascular and other diseases, as well as the results of surgical treatment in patients by assessing the concentration of atrial, brain natriuretic peptides, polymorphic gene variants of these peptides and their receptors. Significant prospects for further research in this direction have been identified in order to develop prognostic molecular genetic panels for assessing the risk of developing myocardial infarction, arterial hypertension, heart failure in the framework of primary and secondary prevention.

кардиоваскулярный рискинфаркт миокарданатрийуретические пептидыоднонуклеотидные полиморфизмыcardiovascular riskmyocardial infarctionnatriuretic peptidessingle nucleotide polymorphismsРабота над обзорной статей осуществлялась в рамках темы № 0419-2022-0001 «Молекулярные, клеточные и биомеханические механизмы патогенеза сердечно-сосудистых заболеваний в разработке новых методов лечения заболеваний сердечно-сосудистой системы на основе персонифицированной фармакотерапии, внедрения малоинвазивных медицинских изделий, биоматериалов и тканеинженерных имплантатов» (научный руководитель – академик РАН Л. С. Барбараш), № госрегистрации 122011900095-2 от 19.01.2022. Утверждена решением Ученого совета НИИ КПССЗ № 15 от 24.12.2021.Research on the review articles was carried out under topic № 0419-2022-0001 «Molecular, cellular and biomechanical mechanisms of the pathogenesis of cardiovascular diseases in the development of new methods of treatment for cardiovascular system diseases based on personalized pharmacotherapy, implementation of minimally invasive medical devices, biomaterials and tissueengineered implants» (Principal Investigator – Academician of the Russian Academy of Sciences L. S. Barbarash) Registration № 122011900095-2 dated as of 19.01.2022. Received approval by the Scientific Council of the Research Institute, protocol № 15 dated as of 12.24.2021.ReferencesBansilal S., Castellano J.M., Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int. J. Cardiol., 2015 Dec; 201 Suppl 1: S1–S7. doi: 10.1016/S0167-5273(15)31026-3Bansilal S., Castellano J.M., Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int. J. Cardiol., 2015 Dec; 201 Suppl 1: S1–S7. doi: 10.1016/S0167-5273(15)31026-3Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., Hindy G., Hólm H., Ding E.L., Johnson T., Schunkert H., Samani N.J., Clarke R., Hopewell J.C., Thompson J.F., Li M., Thorleifsson G., Newton- Cheh C., Musunuru K., Pirruccello J.P., Saleheen D., Chen L., Stewart A., Schillert A., Thorsteinsdottir U., Thorgeirsson G., Anand S., Engert J.C., Morgan T., Spertus J., Stoll M., Berger K., Martinelli N., Girelli D., McKeown P.P., Patterson C.C., Epstein S.E., Devaney J., Burnett M.S., Mooser V., Ripatti S., Surakka I., Nieminen M.S., Sinisalo J., Lokki M.L., Perola M., Havulinna A., de Faire U., Gigante B., Ingelsson E., Zeller T., Wild P., de Bakker P.I., Klungel O.H., Maitland-van der Zee A.H., Peters B.J., de Boer A., Grobbee D.E., Kamphuisen P.W., Deneer V.H., Elbers C.C., Onland-Moret N.C., Hofker M.H., Wijmenga C., Verschuren W.M., Boer J.M., van der Schouw Y.T., Rasheed A., Frossard P., Demissie S., Willer C., Do R., Ordovas J.M., Abecasis G.R., Boehnke M., Mohlke K.L., Daly M.J., Guiducci C., Burtt N.P., Surti A., Gonzalez E., Purcell S., Gabriel S., Marrugat J., Peden J., Erdmann J., Diemert P., Willenborg C., König I.R., Fischer M., Hengstenberg C., Ziegler A., Buysschaert I., Lambrechts D., van de Werf F., Fox K.A., El Mokhtari N.E., Rubin D., Schrezenmeir J., Schreiber S., Schäfer A., Danesh J., Blankenberg S., Roberts R., McPherson R., Watkins H., Hall A.S., Overvad K., Rimm E., Boerwinkle E., Tybjaerg- Hansen A., Cupples L.A., Reilly M.P., Melander O., Mannucci P.M., Ardissino D., Siscovick D., Elosua R., Stefansson K., O’Donnell C.J., Salomaa V., Rader D.J., Peltonen L., Schwartz S.M., Altshuler D., Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, 2012 Aug 11; 380 (9841): 572–580. doi: 10.1016/S0140-6736(12)60312-2Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., Hindy G., Hólm H., Ding E.L., Johnson T., Schunkert H., Samani N.J., Clarke R., Hopewell J.C., Thompson J.F., Li M., Thorleifsson G., Newton- Cheh C., Musunuru K., Pirruccello J.P., Saleheen D., Chen L., Stewart A., Schillert A., Thorsteinsdottir U., Thorgeirsson G., Anand S., Engert J.C., Morgan T., Spertus J., Stoll M., Berger K., Martinelli N., Girelli D., McKeown P.P., Patterson C.C., Epstein S.E., Devaney J., Burnett M.S., Mooser V., Ripatti S., Surakka I., Nieminen M.S., Sinisalo J., Lokki M.L., Perola M., Havulinna A., de Faire U., Gigante B., Ingelsson E., Zeller T., Wild P., de Bakker P.I., Klungel O.H., Maitland-van der Zee A.H., Peters B.J., de Boer A., Grobbee D.E., Kamphuisen P.W., Deneer V.H., Elbers C.C., Onland-Moret N.C., Hofker M.H., Wijmenga C., Verschuren W.M., Boer J.M., van der Schouw Y.T., Rasheed A., Frossard P., Demissie S., Willer C., Do R., Ordovas J.M., Abecasis G.R., Boehnke M., Mohlke K.L., Daly M.J., Guiducci C., Burtt N.P., Surti A., Gonzalez E., Purcell S., Gabriel S., Marrugat J., Peden J., Erdmann J., Diemert P., Willenborg C., König I.R., Fischer M., Hengstenberg C., Ziegler A., Buysschaert I., Lambrechts D., van de Werf F., Fox K.A., El Mokhtari N.E., Rubin D., Schrezenmeir J., Schreiber S., Schäfer A., Danesh J., Blankenberg S., Roberts R., McPherson R., Watkins H., Hall A.S., Overvad K., Rimm E., Boerwinkle E., Tybjaerg- Hansen A., Cupples L.A., Reilly M.P., Melander O., Mannucci P.M., Ardissino D., Siscovick D., Elosua R., Stefansson K., O’Donnell C.J., Salomaa V., Rader D.J., Peltonen L., Schwartz S.M., Altshuler D., Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet, 2012 Aug 11; 380 (9841): 572–580. doi: 10.1016/S0140-6736(12)60312-2li j., qin r., wang w., huang z., huang d.l., li t., wang f., zeng x.t., sun z.y., liu x.f., huang f., guo t. relationship between snp rs1764391 and susceptibility, risk factors, gene-environment interactions of acute myocardial infarction in guangxi han chinese population. curr. pharm. biotechnol., 2020; 21 (1): 79–88. doi: 10.2174/1389201019666191003150015li j., qin r., wang w., huang z., huang d.l., li t., wang f., zeng x.t., sun z.y., liu x.f., huang f., guo t. relationship between snp rs1764391 and susceptibility, risk factors, gene-environment interactions of acute myocardial infarction in guangxi han chinese population. curr. pharm. biotechnol., 2020; 21 (1): 79–88. doi: 10.2174/1389201019666191003150015Oristrell G., Ribera A.. Evolution of the prognosis of acute myocardial infarction. Med. Clin. (Barc.), 2023 Feb 10; 160 (3): 118–120. English, Spanish. doi: 10.1016/j.medcli.2022.07.014Oristrell G., Ribera A.. Evolution of the prognosis of acute myocardial infarction. Med. Clin. (Barc.), 2023 Feb 10; 160 (3): 118–120. English, Spanish. doi: 10.1016/j.medcli.2022.07.014Pan-Lizcano R., Mariñas-Pardo L., Núñez L., Rebollal-Leal F., López-Vázquez D., Pereira A., Molina-Nieto A., Calviño R., Vázquez-Rodríguez J.M., Hermida-Prieto M. Rare Variants in Genes of the Cholesterol Pathway Are Present in 60 % of Patients with Acute Myocardial Infarction. Int. J. Mol. Sci., 2022 Dec 17; 23 (24): 16127. doi: 10.3390/ijms232416127Pan-Lizcano R., Mariñas-Pardo L., Núñez L., Rebollal-Leal F., López-Vázquez D., Pereira A., Molina-Nieto A., Calviño R., Vázquez-Rodríguez J.M., Hermida-Prieto M. Rare Variants in Genes of the Cholesterol Pathway Are Present in 60 % of Patients with Acute Myocardial Infarction. Int. J. Mol. Sci., 2022 Dec 17; 23 (24): 16127. doi: 10.3390/ijms232416127Mars N., Koskela J.T., Ripatti P., Kiiskinen T.T.J., Havulinna A.S., Lindbohm J.V. et al. Polygenic and clinical risk scores and their 308 impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat. Med., 2020; 26 (4): 549–557.Mars N., Koskela J.T., Ripatti P., Kiiskinen T.T.J., Havulinna A.S., Lindbohm J.V. et al. Polygenic and clinical risk scores and their 308 impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat. Med., 2020; 26 (4): 549–557.Boileau A., Lalem T., Vausort M., Zhang L., Devaux Y.; Cardiolinc network (www.cardiolinc.org). A 3-gene panel improves the prediction of left ventricular dysfunction after acute myocardial infarction. Int. J. Cardiol., 2018 Mar 1; 254: 28–35. doi: 10.1016/j.ijcard.2017.10.109Boileau A., Lalem T., Vausort M., Zhang L., Devaux Y.; Cardiolinc network (www.cardiolinc.org). A 3-gene panel improves the prediction of left ventricular dysfunction after acute myocardial infarction. Int. J. Cardiol., 2018 Mar 1; 254: 28–35. doi: 10.1016/j.ijcard.2017.10.109Гончарова И.А., Королева Ю.А., Слепцов А.А., Печерина Т.Б., Кашталап В.В., Пузырев В.П., Назаренко М.С. Генетическая структура подверженности коморбидности сердечно-сосудистого континуума. Генетика, 2022; 58 (10): 1197–1209. doi: 10.31857/S0016675822100034Goncharova I.A., Koroleva Yu.A., Sleptsov A.A., Pecherina T.B., Kashtalap V.V., Puzyrev V.P., Nazarenko M.S. Genetic Structure of Susceptibility to Cardiovascular Continuum Comorbidity. Genetics, 2022; 58 (10): 1197–1209 (in Russ.)Jefferson B.K., Topol E.J. Molecular mechanisms of myocardial infarction. Curr. Probl. Cardiol., 2005 Jul; 30 (7): 333–374. doi: 10.1016/j.cpcardiol.2005.02.002Jefferson B.K., Topol E.J. Molecular mechanisms of myocardial infarction. Curr. Probl. Cardiol., 2005 Jul; 30 (7): 333–374. doi: 10.1016/j.cpcardiol.2005.02.002Goncharova I.A., Nazarenko M.S., Babushkina N.P., Markov A.V., Pecherina T.B., Kashtalap V.V., Tarasenko N.V., Ponasenko A.V., Barbarash O.L., Puzyrev V.P. Genetic Predisposition to Early Myocardial Infarction. Mol. Biol. (Mosk)., 2020 Mar-Apr; 54 (2): 224–232. doi: 10.31857/S0026898420020044Goncharova I.A., Nazarenko M.S., Babushkina N.P., Markov A.V., Pecherina T.B., Kashtalap V.V., Tarasenko N.V., Ponasenko A.V., Barbarash O.L., Puzyrev V.P. Genetic Predisposition to Early Myocardial Infarction. Mol. Biol. (Mosk)., 2020 Mar-Apr; 54 (2): 224–232. doi: 10.31857/S0026898420020044Ложкина Н.Г., Толмачева А.А., Хасанова М.Х., Козик В.А., Стафеева Е.А., Найдена Е.А., Мукарамов И., Барбарич В.Б., Пархоменко О.М., Куимов А.Д., Максимов В.Н., Воевода М.И. Генетические предикторы пятилетних исходов перенесенного острого коронарного синдрома. Рос. кардиол. журн., 2019; 24 (10): 86–90. doi:10.15829/1560-4071-2019-10-86-90Lozhkina N.G., Tolmacheva A.A., Khasanova M.X., Kozik V.A., Stafeeva E.A., Naydena E.A., Mukaramov I., Barbarich V.B., Parkhomenko O.M., Kuimov A.D., Maksimov V.N., Voevoda M.I. Genetic predictors of five-year outcomes of acute coronary syndrome. Rus. J. Cardiol., 2019; 24 (10): 86–90 (in Russ.)Sejrup J.K., Morelli V.M., Løchen M.L., Njølstad I., Mathiesen E.B., Wilsgaard T., Hansen J.B., Brækkan S.K. Myocardial infarction, prothrombotic genotypes, and venous thrombosis risk: The Tromsø Study. Res. Pract. Thromb. Haemost., 2020 Jan 27; 4 (2): 247–254. doi: 10.1002/rth2.12306Sejrup J.K., Morelli V.M., Løchen M.L., Njølstad I., Mathiesen E.B., Wilsgaard T., Hansen J.B., Brækkan S.K. Myocardial infarction, prothrombotic genotypes, and venous thrombosis risk: The Tromsø Study. Res. Pract. Thromb. Haemost., 2020 Jan 27; 4 (2): 247–254. doi: 10.1002/rth2.12306Chen Q.F., Wang W., Huang Z., Huang D.L., Li T., Wang F., Li J. Correlation of rs1122608 SNP with acute myocardial infarction susceptibility and clinical characteristics in a Chinese Han population: A casecontrol study. Anatol. J. Cardiol., 2018 Apr; 19 (4): 249–258. doi: 10.14744/AnatolJCardiol.2018.35002Chen Q.F., Wang W., Huang Z., Huang D.L., Li T., Wang F., Li J. Correlation of rs1122608 SNP with acute myocardial infarction susceptibility and clinical characteristics in a Chinese Han population: A casecontrol study. Anatol. J. Cardiol., 2018 Apr; 19 (4): 249–258. doi: 10.14744/AnatolJCardiol.2018.35002Li J., Qin R., Wang W., Huang Z., Huang D.L., Li T., Wang F., Zeng X.T., Sun Z.Y., Liu X.F., Huang F., Guo T. Relationship between SNP rs1764391 and Susceptibility, Risk Factors, Gene-environment Interactions of Acute Myocardial Infarction in Guangxi Han Chinese Population. Curr. Pharm. Biotechnol., 2020; 21 (1): 79–88. doi: 10.2174/1389201019666191003150015Li J., Qin R., Wang W., Huang Z., Huang D.L., Li T., Wang F., Zeng X.T., Sun Z.Y., Liu X.F., Huang F., Guo T. Relationship between SNP rs1764391 and Susceptibility, Risk Factors, Gene-environment Interactions of Acute Myocardial Infarction in Guangxi Han Chinese Population. Curr. Pharm. Biotechnol., 2020; 21 (1): 79–88. doi: 10.2174/1389201019666191003150015Tanaka T., Ozaki K. Inflammation as a risk factor for myocardial infarction. J. Hum. Genet., 2006; 51 (7): 595–604. doi: 10.1007/s10038-006-0411-8Tanaka T., Ozaki K. Inflammation as a risk factor for myocardial infarction. J. Hum. Genet., 2006; 51 (7): 595–604. doi: 10.1007/s10038-006-0411-8Song G.Y., Wu Y.J., Yang Y.J., Li J.J., Zhang H.L., Pei H.J., Zhao Z.Y., Zeng Z.H., Hui R.T. The accelerated post-infarction progression of cardiac remodelling is associated with genetic changes in an untreated streptozotocin-induced diabetic rat model. Eur. J. Heart Fail., 2009 Oct; 11 (10): 911–921. doi: 10.1093/eurjhf/hfp117Song G.Y., Wu Y.J., Yang Y.J., Li J.J., Zhang H.L., Pei H.J., Zhao Z.Y., Zeng Z.H., Hui R.T. The accelerated post-infarction progression of cardiac remodelling is associated with genetic changes in an untreated streptozotocin-induced diabetic rat model. Eur. J. Heart Fail., 2009 Oct; 11 (10): 911–921. doi: 10.1093/eurjhf/hfp117Чаулин А.М., Дупляков Д.В. Повышение натрийуретических пептидов, не ассоциированное с сердечной недостаточностью. Рос. кардиол. журн., 2020; 25 (S4): 4140. doi: 10.15829/1560-4071-2020-4140Chaulin A.M., Duplyakov D.V. Increased natriuretic peptides not associated with heart failure. Rus. J. Cardiol., 2020; 25 (S4): 4140. (In Russ.)Goetze J.P., Bruneau B.G., Ramos H.R., Ogawa T., de Bold M.K., de Bold A.J. Cardiac natriuretic peptides. Nat. Rev. Cardiol., 2020 Nov; 17 (11): 698–717. doi: 10.1038/s41569-020-0381-0Goetze J.P., Bruneau B.G., Ramos H.R., Ogawa T., de Bold M.K., de Bold A.J. Cardiac natriuretic peptides. Nat. Rev. Cardiol., 2020 Nov; 17 (11): 698–717. doi: 10.1038/s41569-020-0381-0de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci., 1981; 28: 89–94.de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci., 1981; 28: 89–94.Nishikimi T., Kuwahara K., Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J. Cardiol., 2011; 57 (2): 131–140. doi:10.1016/j.jjcc.2011.01.002Nishikimi T., Kuwahara K., Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J. Cardiol., 2011; 57 (2): 131–140. doi:10.1016/j.jjcc.2011.01.002Hall C. Essential biochemistry and physiology of (NTpro) BNP. Eur. J. Heart Fail., 2004; 6 (3): 257–260. doi: 10.1016/j.ejheart.2003.12.015Hall C. Essential biochemistry and physiology of (NTpro) BNP. Eur. J. Heart Fail., 2004; 6 (3): 257–260. doi: 10.1016/j.ejheart.2003.12.015Abassi Z., Karram T., Ellaham S. et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol. Ther., 2004; 102 (3): 223–241. doi: 10.1016/j.pharmthera.2004.04.004Abassi Z., Karram T., Ellaham S. et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol. Ther., 2004; 102 (3): 223–241. doi: 10.1016/j.pharmthera.2004.04.004Joharimoghadam A., Tajdini M., Bozorgi A. Salivary B-type natriuretic peptide: a new method for heart failure diagnosis and follow-up. Kardiol. Pol., 2017; 75 (1): 71–77. doi: 10.5603/KP.a2016.0097Joharimoghadam A., Tajdini M., Bozorgi A. Salivary B-type natriuretic peptide: a new method for heart failure diagnosis and follow-up. Kardiol. Pol., 2017; 75 (1): 71–77. doi: 10.5603/KP.a2016.0097Hall C. NT-ProBNP: the mechanism behind the marker. J. Card. Fail., 2005 Jun; 11 (5 Suppl): S81–S83. doi: 10.1016/j.cardfail.2005.04.019Hall C. NT-ProBNP: the mechanism behind the marker. J. Card. Fail., 2005 Jun; 11 (5 Suppl): S81–S83. doi: 10.1016/j.cardfail.2005.04.019Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N. Engl. J. Med., 1998 Jul 30; 339 (5): 321–328. doi: 10.1056/NEJM199807303390507Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N. Engl. J. Med., 1998 Jul 30; 339 (5): 321–328. doi: 10.1056/NEJM199807303390507Okamoto R., Ali Y., Hashizume R., Suzuki N., Ito M. BNP as a Major Player in the Heart-Kidney Connection. Int. J. Mol. Sci., 2019 Jul 22; 20 (14): 3581. doi: 10.3390/ijms20143581Okamoto R., Ali Y., Hashizume R., Suzuki N., Ito M. BNP as a Major Player in the Heart-Kidney Connection. Int. J. Mol. Sci., 2019 Jul 22; 20 (14): 3581. doi: 10.3390/ijms20143581Oikonomou E., Zografos T., Papamikroulis G.A., Siasos G., Vogiatzi G., Theofilis P., Briasoulis A., Papaioannou S., Vavuranakis M., Gennimata V., Tousoulis D. Biomarkers in Atrial Fibrillation and Heart Failure. Curr. Med. Chem., 2019; 26 (5): 873–887. doi: 10.2174/0929867324666170830100424Oikonomou E., Zografos T., Papamikroulis G.A., Siasos G., Vogiatzi G., Theofilis P., Briasoulis A., Papaioannou S., Vavuranakis M., Gennimata V., Tousoulis D. Biomarkers in Atrial Fibrillation and Heart Failure. Curr. Med. Chem., 2019; 26 (5): 873–887. doi: 10.2174/0929867324666170830100424Ovchinnikov A.G., Gvozdeva A.D., Blankova Z.N., Borisov A.A., Ageev F.T. The Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction. Kardiologiia, 2020 Dec 15; 60 (11): 1352. doi: 10.18087/cardio.2020.11.n1352Ovchinnikov A.G., Gvozdeva A.D., Blankova Z.N., Borisov A.A., Ageev F.T. The Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction. Kardiologiia, 2020 Dec 15; 60 (11): 1352. doi: 10.18087/cardio.2020.11.n1352Heyse A., Manhaeghe L., Mahieu E., Vanfraechem C., van Durme F. Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail., 2019 Dec; 6 (6): 1331–1333. doi: 10.1002/ehf2.12544Heyse A., Manhaeghe L., Mahieu E., Vanfraechem C., van Durme F. Sacubitril/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail., 2019 Dec; 6 (6): 1331–1333. doi: 10.1002/ehf2.12544Singh J.S.S., Burrell L.M., Cherif M., Squire I.B., Clark A.L., Lang C.C. Sacubitril/valsartan: beyond natriuretic peptides. Heart, 2017 Oct; 103 (20): 1569–1577. doi: 10.1136/heartjnl-2017-311295Singh J.S.S., Burrell L.M., Cherif M., Squire I.B., Clark A.L., Lang C.C. Sacubitril/valsartan: beyond natriuretic peptides. Heart, 2017 Oct; 103 (20): 1569–1577. doi: 10.1136/heartjnl-2017-311295McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., Cleland J.G.F., Coats A.J.S., Crespo-Leiro M.G., Farmakis D., Gilard M., Heymans S., Hoes A.W., Jaarsma T., Jankowska E.A., Lainscak M., Lam CSP, Lyon A.R., McMurray J.J.V., Mebazaa A., Mindham R., Muneretto C., Francesco Piepoli M., Price S., Rosano G.M.C., Ruschitzka F., Kathrine Skibelund A.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J., 2021 Sep 21; 42 (36): 3599–3726. doi: 10.1093/eurheartj/ehab368McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., Čelutkienė J., Chioncel O., Cleland J.G.F., Coats A.J.S., Crespo-Leiro M.G., Farmakis D., Gilard M., Heymans S., Hoes A.W., Jaarsma T., Jankowska E.A., Lainscak M., Lam CSP, Lyon A.R., McMurray J.J.V., Mebazaa A., Mindham R., Muneretto C., Francesco Piepoli M., Price S., Rosano G.M.C., Ruschitzka F., Kathrine Skibelund A.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J., 2021 Sep 21; 42 (36): 3599–3726. doi: 10.1093/eurheartj/ehab368Mahla E., Baumann A., Rehak P., Watzinger N., Vicenzi M.N., Maier R., Tiesenhausen K., Metzler H., Toller W. N-Terminal Pro-brain Natriuretic Peptide Identifies Patients at High Risk for Adverse Cardiac Outcome after Vascular Surgery. Anesthesiology, 2007; 106: 1088–1095.Mahla E., Baumann A., Rehak P., Watzinger N., Vicenzi M.N., Maier R., Tiesenhausen K., Metzler H., Toller W. N-Terminal Pro-brain Natriuretic Peptide Identifies Patients at High Risk for Adverse Cardiac Outcome after Vascular Surgery. Anesthesiology, 2007; 106: 1088–1095.Ma J., Xin Q., Wang X., Gao M., Wang Y., Liu J. Prediction of perioperative cardiac events through preoperative NT-pro-BNP and cTnI after emergent non-cardiac surgery in elderly patients. PLoS One, 2015 Mar 23; 10 (3): e0121306. doi: 10.1371/journal.pone.0121306Ma J., Xin Q., Wang X., Gao M., Wang Y., Liu J. Prediction of perioperative cardiac events through preoperative NT-pro-BNP and cTnI after emergent non-cardiac surgery in elderly patients. PLoS One, 2015 Mar 23; 10 (3): e0121306. doi: 10.1371/journal.pone.0121306Halvorsen S., Mehilli J., Cassese S., Hall T.S., Abdelhamid M., Barbato E., de Hert S., de Laval I., Geisler T., Hinterbuchner L., Ibanez B., Lenarczyk R., Mansmann U.R., McGreavy P., Mueller C., Muneretto C., Niessner A., Potpara T.S., Ristić A., Sade L.E., Schirmer H., Schüpke S., Sillesen H., Skulstad H., Torracca L., Tutarel O., van der Meer P., Wojakowski W., Zacharowski K.; ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur. Heart J., 2022 Oct 14; 43 (39): 3826–3924. doi: 10.1093/eurheartj/ehac270Halvorsen S., Mehilli J., Cassese S., Hall T.S., Abdelhamid M., Barbato E., de Hert S., de Laval I., Geisler T., Hinterbuchner L., Ibanez B., Lenarczyk R., Mansmann U.R., McGreavy P., Mueller C., Muneretto C., Niessner A., Potpara T.S., Ristić A., Sade L.E., Schirmer H., Schüpke S., Sillesen H., Skulstad H., Torracca L., Tutarel O., van der Meer P., Wojakowski W., Zacharowski K.; ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur. Heart J., 2022 Oct 14; 43 (39): 3826–3924. doi: 10.1093/eurheartj/ehac270Мурашко С.С., Пасечник И.Н., Бернс С.А. Миокардиальное повреждение при некардиальной хирургии: трудности диагностики. Комплексные проблемы сердечно-сосудистых заболеваний, 2020; 9 (3): 59–68. doi: 10.17802/2306-1278-2020-9-3-59-68Murashko S.S., Pasechnik I.N., Berns S.A. Myocardial injury in noncardiac surgery – diagnostic difficulties. Comp. Iss. Cardiovascular Diseases, 2020; 9 (3): 59–68 (in Russ.)Chiba A., Watanabe-Takano H., Miyazaki T., Mochizuki N. Cardiomyokines from the heart. Cell Mol. Life Sci., 2018 Apr; 75 (8): 1349–1362. doi: 10.1007/s00018-017-2723-6Chiba A., Watanabe-Takano H., Miyazaki T., Mochizuki N. Cardiomyokines from the heart. Cell Mol. Life Sci., 2018 Apr; 75 (8): 1349–1362. doi: 10.1007/s00018-017-2723-6Барбараш О.Л., Усольцева Е.Н., Шафранская К.С., Зыков М.В., Груздева О.В., Поликутина О.М., Кашталап В.В. Возможность использования N-терминального фрагмента мозгового натрий-уретического пропептида как маркера мультифокального атеросклероза у больных инфарктом миокарда с подъемом сегмента ST. Рос. кардиол. журн., 2012; 3 (95): 12–18. elibrary ID: 17745435 EDN: OYIKLHBarbarash O.L., Usoltseva E.N., Shafranskaya K.S., Zykov M.V., Gruzdeva O.V., Polikutina O.M., Kashtalap V.V. N-terminal brain natriuretic propeptide as a marker of multifocal atherosclerosis in patients with ST segment elevation myocardial infarction. Russ. J. Cardiol., 2012; 3 (95): 12–18. (in Russ.)Park Y.H., Park H.J., Kim B.S., Ha E., Jung K.H., Yoon S.H., Yim S.V., Chung J.H. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer. Lett., 2006 Nov 8; 243 (1): 16–22. doi: 10.1016/j.canlet.2005.11.014Park Y.H., Park H.J., Kim B.S., Ha E., Jung K.H., Yoon S.H., Yim S.V., Chung J.H. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer. Lett., 2006 Nov 8; 243 (1): 16–22. doi: 10.1016/j.canlet.2005.11.014Lanfear D.E. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev., 2010 May; 15 (3): 219–228. doi: 10.1007/s10741-008-9113-yLanfear D.E. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev., 2010 May; 15 (3): 219–228. doi: 10.1007/s10741-008-9113-yAbuzaanona A., Lanfear D. Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Curr. Heart Fail Rep., 2017 Dec; 14 (6): 536–542. doi: 10.1007/s11897-017-0365-5Abuzaanona A., Lanfear D. Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Curr. Heart Fail Rep., 2017 Dec; 14 (6): 536–542. doi: 10.1007/s11897-017-0365-5Pitzalis M.V., Sarzani R., Dessi-Fulgheri P., Iacoviello M., Forleo C., Lucarelli K., Pietrucci F., Salvi F., Sorrentino S., Romito R., Guida P., Rappelli A., Rizzon P. Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J. Hypertens., 2003; 21: 1491–1496.Pitzalis M.V., Sarzani R., Dessi-Fulgheri P., Iacoviello M., Forleo C., Lucarelli K., Pietrucci F., Salvi F., Sorrentino S., Romito R., Guida P., Rappelli A., Rizzon P. Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J. Hypertens., 2003; 21: 1491–1496.Rubattu S., Stanzione R., di Angelantonio E., Zanda B., Evangelista A., Tarasi D., Gigante B., Pirisi A., Brunetti E., Volpe M. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke, 2004; 35: 814–818.Rubattu S., Stanzione R., di Angelantonio E., Zanda B., Evangelista A., Tarasi D., Gigante B., Pirisi A., Brunetti E., Volpe M. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke, 2004; 35: 814–818.Gruchala M., Ciećwierz D., Wasag B., Targoński R., Dubaniewicz W., Nowak A., Sobiczewski W., Ochman K., Romanowski P., Limon J., Rynkiewicz A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am. Heart J., 2003 Jan; 145 (1): 125–131. doi: 10.1067/mhj.2003.52Gruchala M., Ciećwierz D., Wasag B., Targoński R., Dubaniewicz W., Nowak A., Sobiczewski W., Ochman K., Romanowski P., Limon J., Rynkiewicz A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am. Heart J., 2003 Jan; 145 (1): 125–131. doi: 10.1067/mhj.2003.52Niu W. The Relationship between Natriuretic Peptide Precursor a Gene T2238C Polymorphism and Hypertension: A Meta-Analysis. Int. J. Hypertens., 2011; 2011: 653698. doi: 10.4061/2011/653698Niu W. The Relationship between Natriuretic Peptide Precursor a Gene T2238C Polymorphism and Hypertension: A Meta-Analysis. Int. J. Hypertens., 2011; 2011: 653698. doi: 10.4061/2011/653698Fox A.A., Collard C.D., Shernan S.K., Seidman C.E., Seidman J.G., Liu K.Y., Muehlschlegel J.D., Perry T.E., Aranki S.F., Lange C., Herman D.S., Meitinger T., Lichtner P., Body S.C. Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology, 2009 Apr; 110 (4): 738–747. doi: 10.1097/aln.0b013e31819c7496Fox A.A., Collard C.D., Shernan S.K., Seidman C.E., Seidman J.G., Liu K.Y., Muehlschlegel J.D., Perry T.E., Aranki S.F., Lange C., Herman D.S., Meitinger T., Lichtner P., Body S.C. Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology, 2009 Apr; 110 (4): 738–747. doi: 10.1097/aln.0b013e31819c7496Takeishi Y., Toriyama S., Takabatake N., Shibata Y., Konta T., Emi M., Kato T., Kawata S., Kubota I. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem. Biophys. Res. Commun., 2007 Oct 19; 362 (2): 480–484. doi: 10.1016/j.bbrc.2007.08.028Takeishi Y., Toriyama S., Takabatake N., Shibata Y., Konta T., Emi M., Kato T., Kawata S., Kubota I. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem. Biophys. Res. Commun., 2007 Oct 19; 362 (2): 480–484. doi: 10.1016/j.bbrc.2007.08.028Iemitsu M., Maeda S., Otsuki T., Sugawara J., Kuno S., Ajisaka R., Matsuda M. Arterial stiffness, physical activity, and atrial natriuretic Peptide gene polymorphism in older subjects. Hypertens. Res., 2008 Apr; 31 (4): 767–774. doi: 10.1291/hypres.31.767Iemitsu M., Maeda S., Otsuki T., Sugawara J., Kuno S., Ajisaka R., Matsuda M. Arterial stiffness, physical activity, and atrial natriuretic Peptide gene polymorphism in older subjects. Hypertens. Res., 2008 Apr; 31 (4): 767–774. doi: 10.1291/hypres.31.767Carnevale R., Pignatelli P., Frati G., Nocella C., Stanzione R., Pastori D., Marchitti S., Valenti V., Santulli M., Barbato E., Strisciuglio T., Schirone L., Vecchione C., Violi F., Volpe M., Rubattu S., Sciarretta S. C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. Sci. Rep., 2017 Jun 19; 7 (1): 3797. doi: 10.1038/s41598-017-03679-9Carnevale R., Pignatelli P., Frati G., Nocella C., Stanzione R., Pastori D., Marchitti S., Valenti V., Santulli M., Barbato E., Strisciuglio T., Schirone L., Vecchione C., Violi F., Volpe M., Rubattu S., Sciarretta S. C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. Sci. Rep., 2017 Jun 19; 7 (1): 3797. doi: 10.1038/s41598-017-03679-9Rubattu S., Sciarretta S., Marchitti S., Bianchi F., Forte M., Volpe M. The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases. Int. J. Mol. Sci., 2018 Feb 11; 19 (2): 540. doi: 10.3390/ijms19020540Rubattu S., Sciarretta S., Marchitti S., Bianchi F., Forte M., Volpe M. The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases. Int. J. Mol. Sci., 2018 Feb 11; 19 (2): 540. doi: 10.3390/ijms19020540Larifla L., Maimaitiming S., Velayoudom-Cephise F.L., Ferdinand S., Blanchet-Deverly A., Benabdallah S., Donnet J.P., Atallah A., Roussel R., Foucan L. Association of 2238T>C polymorphism of the atrial natriuretic peptide gene with coronary artery disease in Afro-Caribbeans with type 2 diabetes. Am. J. Hypertens., 2012 May; 25 (5): 524–527. doi: 10.1038/ajh.2011.233Larifla L., Maimaitiming S., Velayoudom-Cephise F.L., Ferdinand S., Blanchet-Deverly A., Benabdallah S., Donnet J.P., Atallah A., Roussel R., Foucan L. Association of 2238T>C polymorphism of the atrial natriuretic peptide gene with coronary artery disease in Afro-Caribbeans with type 2 diabetes. Am. J. Hypertens., 2012 May; 25 (5): 524–527. doi: 10.1038/ajh.2011.233Meroufel D.N., Ouhaïbi-Djellouli H., Mediene-Benchekor S., Hermant X., Grenier-Boley B., Lardjam-Hetraf S.A., Boulenouar H., Hamani-Medjaoui I., Saïdi-Mehtar N., Amouyel P., Houti L., Goumidi L., Meirhaeghe A. Examination of the brain natriuretic peptide rs198389 single-nucleotide polymorphism on type 2 diabetes mellitus and related phenotypes in an Algerian population. Gene, 2015 Aug 10; 567 (2): 159–163. doi: 10.1016/j.gene.2015.04.073Meroufel D.N., Ouhaïbi-Djellouli H., Mediene-Benchekor S., Hermant X., Grenier-Boley B., Lardjam-Hetraf S.A., Boulenouar H., Hamani-Medjaoui I., Saïdi-Mehtar N., Amouyel P., Houti L., Goumidi L., Meirhaeghe A. Examination of the brain natriuretic peptide rs198389 single-nucleotide polymorphism on type 2 diabetes mellitus and related phenotypes in an Algerian population. Gene, 2015 Aug 10; 567 (2): 159–163. doi: 10.1016/j.gene.2015.04.073Jin G., Chen Z., Zhang J., Song J., Shi J., Zhou B. Association of brain natriuretic peptide gene polymorphisms with chronic obstructive pulmonary disease complicated with pulmonary hypertension and its mechanism. Biosci. Rep., 2018 Oct 2; 38 (5): BSR20180905. doi: 10.1042/BSR20180905Jin G., Chen Z., Zhang J., Song J., Shi J., Zhou B. Association of brain natriuretic peptide gene polymorphisms with chronic obstructive pulmonary disease complicated with pulmonary hypertension and its mechanism. Biosci. Rep., 2018 Oct 2; 38 (5): BSR20180905. doi: 10.1042/BSR20180905Poreba R., Poczatek K., Gać P., Poreba M., Gonerska M., Jonkisz A., Derkacz A., Negrusz-Kawecka M., Sobieszczańska M., Pilecki W., Szuba A., Andrzejak R. SNP rs198389 (T-381 C) polymorphism in the B-type natriuretic peptide gene promoter in patients with atherosclerotic renovascular hypertension. Pol. Arch. Med. Wewn., 2009 Apr; 119 (4): 219–224.Poreba R., Poczatek K., Gać P., Poreba M., Gonerska M., Jonkisz A., Derkacz A., Negrusz-Kawecka M., Sobieszczańska M., Pilecki W., Szuba A., Andrzejak R. SNP rs198389 (T-381 C) polymorphism in the B-type natriuretic peptide gene promoter in patients with atherosclerotic renovascular hypertension. Pol. Arch. Med. Wewn., 2009 Apr; 119 (4): 219–224.Березикова Е.Н., Маянская С.Д., Гараева Л.А., Шилов С.Н., Ефремов А.В., Тепляков А.Т., Сафронов И.Д., Пустоветова М.Г., Самсонова Е.Н., Торим Ю.Ю. Полиморфизм гена мозгового натрийуретического пептида у больных с хронической сердечной недостаточностью. Казанск. мед. журн., 2013; 94 (4): 433–438. eLIBRARY ID: 20167657 EDN: QZIODDBerezikova E.N., Mayanskaya S.D., Garaeva L.A., Shilov S.N., Efremov A.V., Teplyakov A.T., Safronov I.D., Pustovetova M.G., Samsonova E.N., Torim Y.Y. Brain natriuretic peptide gene polymorphism in patients with congestive heart failure. Kazan Med. J., 2013; 4 (94): 433–438 (in Russ.)Макеева О.А., Зыков М.В., Голубенко М.В., Кашталап В.В., Кулиш Е.В., Гончарова И.А., Барбараш О.Л., Пузырев В.П. Роль генетических факторов в прогнозировании осложнений на протяжении года после инфаркта миокарда. Кардиология, 2013; 53 (10): 16–23. eLIBRARY ID: 20862065Березикова Е.Н., Маянская С.Д., Гараева Л.А., Шилов С.Н., Ефремов А.В., Тепляков А.Т., Сафронов И.Д., Пустоветова М.Г., Самсонова Е.Н., Торим Ю.Ю. Полиморфизм гена мозгового натрийуретического пептида у больных с хронической сердечной недостаточностью. Казанск. мед. журн., 2013; 94 (4): 433–438. eLIBRARY ID: 20167657 EDN: QZIODDGruchala M., Ciećwierz D., Wasag B., Targoński R., Dubaniewicz W., Nowak A., Sobiczewski W., Ochman K., Romanowski P., Limon J., Rynkiewicz A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am. Heart J., 2003 Jan; 145 (1): 125–131. doi: 10.1067/mhj.2003.52Makeeva O.A., Zykov M.V., Golubenko M.V., Kashtalap V.V., Kuslish E.V., Goncharova I.A., Barbarash O.L., Puzyrev V.P. The role of genetic factors in the prediction of myocardial infarction complications within one year follow up. Kardiologiia, 2013; 53 (10): 16–23 (in Russ.)Siebert J., Lewicki Ł., Myśliwska J., Młotkowska M., Rogowski J. ScaI atrial natriuretic peptide gene polymorphisms and their possible association with postoperative atrial fibrillation – a preliminary report. Arch. Med. Sci., 2017 Apr 1; 13 (3): 568–574. doi: 10.5114/aoms.2016.58270Gruchala M., Ciećwierz D., Wasag B., Targoński R., Dubaniewicz W., Nowak A., Sobiczewski W., Ochman K., Romanowski P., Limon J., Rynkiewicz A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am. Heart J., 2003 Jan; 145 (1): 125–131. doi: 10.1067/mhj.2003.52Yamada Y., Ichihara S., Nishida T. Molecular genetics of myocardial infarction. Genomic. Med., 2008 Jan; 2 (1-2): 7–22. doi: 10.1007/s11568-008-9025-xSiebert J., Lewicki Ł., Myśliwska J., Młotkowska M., Rogowski J. ScaI atrial natriuretic peptide gene polymorphisms and their possible association with postoperative atrial fibrillation – a preliminary report. Arch. Med. Sci., 2017 Apr 1; 13 (3): 568–574. doi: 10.5114/aoms.2016.58270Yamada Y., Ichihara S., Nishida T. Molecular genetics of myocardial infarction. Genomic. Med., 2008 Jan; 2 (1-2): 7–22. doi: 10.1007/s11568-008-9025-xYamada Y., Ichihara S., Nishida T. Molecular genetics of myocardial infarction. Genomic. Med., 2008 Jan; 2 (1-2): 7–22. doi: 10.1007/s11568-008-9025-x

The authors declare that there are no conflicts of interest present.